These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 57451)

  • 21. Bone mineral content in chronic renal failure during long-term treatment with 1alpha-hydroxycholecalciferol.
    Madsen S; Olgaard K; Ladefoged J
    Acta Med Scand; 1978; 203(5):385-9. PubMed ID: 665304
    [No Abstract]   [Full Text] [Related]  

  • 22. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renal osteodystrophy in early chronic renal failure.
    Suzuki M; Hirasawa Y
    Contrib Nephrol; 1980; 22():28-38. PubMed ID: 7398337
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bone composition and vitamin D after Pólya gastrectomy.
    Tougaard L; Rickers H; Rödbro P; Thaysen EH; Christensen MS; Lund B; Sörensen OH
    Acta Med Scand; 1977; 202(1-2):47-50. PubMed ID: 899882
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Action of 1alpha-hydroxy vitamin D3 on calcium absorption and bone resorption in man.
    Peacock M; Gallagher JC; Nordin BE
    Lancet; 1974 Mar; 1(7854):385-89. PubMed ID: 4131034
    [No Abstract]   [Full Text] [Related]  

  • 26. Bone disease and hyperparathyroidism in chronic renal failure: the effect of 1alpha-hydroxyvitamin D3.
    Peacock M; Aaron JE; Walker GS; Davison AM
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():73s-81s. PubMed ID: 606428
    [No Abstract]   [Full Text] [Related]  

  • 27. 1 alpha hydroxycholecalciferol and 25 hydroxycholecalciferol in renal bone disease.
    Fournier AE; Bordier PJ; Gueris J; Chanard J; Marie P; Ferriere C; Osario M; Bedrossian J; de Luca HF
    Proc Eur Dial Transplant Assoc; 1976; 12():227-36. PubMed ID: 935115
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biological activity of endogenous and exogenous calcitonin in patients with osteitis fibrosa and chronic renal failure.
    Cundy T; Heynen G; Paton S; Ledingham JG; Russell RG; Oliver DO; Kanis JA
    Proc Eur Dial Transplant Assoc; 1978; 15():524-31. PubMed ID: 740683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effect of 1 alpha-hydroxycholecalciferol and of a varying phosphorus requirement on mineral metabolism in chronic renal insufficiency].
    Blazheevich NV; Fernándes R; Isaeva VA; Pereverzeva OG; Alekseeva IA
    Vopr Med Khim; 1980; 26(1):13-23. PubMed ID: 7368619
    [TBL] [Abstract][Full Text] [Related]  

  • 30. I alpha-hydroxycholecalciferol: a treatment of renal bone disease.
    Catto GR; MacLeod M; Pelc B; Kodicek E
    Br Med J; 1975 Jan; 1(5948):12-4. PubMed ID: 1120218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 1 alpha-hydroxycholecalciferol in hemodialysis renal osteodystrophy. Adverse effects of anticonvulsant therapy.
    Pierides AM; Kerr DN; Ellis HA; Peart KM; O'Riordan JL; DeLuca HF
    Clin Nephrol; 1976 Apr; 3(2):189-96. PubMed ID: 819195
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 1-alphahydroxycholecalciferol in chronic renal failure. Studies of the effect or oral doses.
    Davie MW; Chalmers TM; Hunter JO; Pelc B; Kodicek E
    Ann Intern Med; 1976 Mar; 84(3):281-5. PubMed ID: 1259263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 1,25-dihydroxycholecalciferol in patients with chronic renal failure.
    Henderson RG; Ledingham JG; Norman AW; Oliver DO; Preston C; Russell RG; Small DG; Smith R; Warner GT; Woods CG
    Proc Eur Dial Transplant Assoc; 1973; 10(0):202-9. PubMed ID: 4802654
    [No Abstract]   [Full Text] [Related]  

  • 34. The impact of fish oil and wheat germ oil combination on mineral-bone and inflammatory markers in maintenance hemodialysis patients: a randomized, double-blind, placebo-controlled clinical trial.
    Zakaria H; Mostafa TM; El-Azab GA; Abd El Wahab AM; Elshahawy H; Sayed-Ahmed NA
    Int Urol Nephrol; 2017 Oct; 49(10):1851-1858. PubMed ID: 28667579
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of phenytoin on bone and vitamin D metabolism.
    Bell RD; Pak CY; Zerwekh J; Barilla DE; Vasko M
    Ann Neurol; 1979 Apr; 5(4):374-8. PubMed ID: 220903
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phosphate and 1alpha-hydroxyvitamin D3 therapy in haemodialysis patients.
    Davison AM; Peacock M; Walker GS; Marshall DH; McLaughlin MS; Robinson PJ
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():91s-99s. PubMed ID: 606431
    [No Abstract]   [Full Text] [Related]  

  • 37. Short-term effects of 1,25-dihydroxycholecalciferol on disordered calcium metabolism of renal failure.
    Brickman AS; Coburn JW; Norman AW; Massry SG
    Am J Med; 1974 Jul; 57(1):28-33. PubMed ID: 4600292
    [No Abstract]   [Full Text] [Related]  

  • 38. Long-term experience of alfacalcidol in renal osteodystrophy.
    Sharman VL; Brownjohn AM; Goodwin FJ; Hately W; Manning RM; O'Riordan JH; Papapoulos SE; Marsh FP
    Q J Med; 1982; 51(203):271-8. PubMed ID: 7146311
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of renal bone disease with 1 alpha-hydroxylated derivatives of vitamin D3. Clinical, biochemical, radiographic and histological responses.
    Kanis JA; Cundy T; Earnshaw M; Henderson RG; Heynen G; Naik R; Russell RG; Smith R; Woods CG
    Q J Med; 1979 Apr; 48(190):289-322. PubMed ID: 504552
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure.
    Rix M; Andreassen H; Eskildsen P; Langdahl B; Olgaard K
    Kidney Int; 1999 Sep; 56(3):1084-93. PubMed ID: 10469378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.